1. Scrip
  2. >>Archive

Generic Tricor could boost Lupin in the US but shadow on Antara

 
• By Anju Ghangurde

Lupin has introduced fenofibrate tablets 48mg and 145mg, generic versions of Abbott's TriCor, on the US market, in what’s seen as a ‘material’ launch for the Indian firm in the short term. The genericisation of Tricor, though, could also potentially dull the prospects of Lupin’s Antara (fenofibrate capsules 43mg and 130mg) brand there, some analysts said.

Lupin has introduced fenofibrate tablets 48mg and 145mg, generic versions of Abbott's TriCor, on the US market, in what’s seen as a ‘material’ launch for the Indian firm in the short term. The genericisation of Tricor, though, could also potentially dull the prospects of Lupin’s Antara (fenofibrate capsules 43mg and 130mg) brand there, some analysts said.

Lupin’s group president and executive director, Nilesh Gupta, told Scrip that it was still ‘early days’ as far as Antara...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.